About Denali Therapeutics (NASDAQ:DNLI)
Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DNLI
CUSIPN/A
Phone650-866-8548
Debt
Debt-to-Equity RatioN/A
Current Ratio28.93%
Quick Ratio28.93%
Price-To-Earnings
Trailing P/E Ratio-3.12
Forward P/E Ratio-32.79
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.29 per share
Price / Book3.47
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees130
Outstanding Shares94,430,000
Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions
What is Denali Therapeutics' stock symbol?
Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."
How were Denali Therapeutics' earnings last quarter?
Denali Therapeutics (NASDAQ:DNLI) posted its quarterly earnings results on Monday, March, 19th. The company reported ($0.74) EPS for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.47. View Denali Therapeutics' Earnings History.
When is Denali Therapeutics' next earnings date?
What price target have analysts set for DNLI?
4 brokerages have issued 1 year target prices for Denali Therapeutics' stock. Their predictions range from $23.00 to $25.00. On average, they anticipate Denali Therapeutics' stock price to reach $24.00 in the next year. View Analyst Ratings for Denali Therapeutics.
Who are some of Denali Therapeutics' key competitors?
Some companies that are related to Denali Therapeutics include Neurocrine Biosciences (NBIX), Bio-Techne (TECH), China Biologic Products (CBPO), Spark Therapeutics (ONCE), arGEN-X BV (ARGX), Halozyme (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Momenta Pharmaceuticals (MNTA) and Audentes Therapeutics (BOLD).
Who are Denali Therapeutics' key executives?
Denali Therapeutics' management team includes the folowing people:
- Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 42)
- Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 45)
- Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 58)
- Mr. Steve E. Krognes, CFO, Principal Accounting Officer & Treasurer (Age 49)
- Dr. Carole Ho M.D., Chief Medical Officer & Head of Devel. (Age 45)
When did Denali Therapeutics IPO?
(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.
When does the company's lock-up period expire?
Denali Therapeutics' lock-up period expires on Wednesday, June 6th. Denali Therapeutics had issued 13,888,888 shares in its initial public offering on December 8th. The total size of the offering was $249,999,984 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
Has Denali Therapeutics been receiving favorable news coverage?
News coverage about DNLI stock has been trending somewhat positive on Thursday, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Denali Therapeutics earned a media sentiment score of 0.09 on Accern's scale. They also gave media headlines about the company an impact score of 44.63 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Denali Therapeutics?
Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Denali Therapeutics' stock price today?
One share of DNLI stock can currently be purchased for approximately $18.36.
How big of a company is Denali Therapeutics?
Denali Therapeutics has a market capitalization of $1.84 billion. The company earns $-88,180,000.00 in net income (profit) each year or ($5.89) on an earnings per share basis. Denali Therapeutics employs 130 workers across the globe.
How can I contact Denali Therapeutics?
Denali Therapeutics' mailing address is 151 OYSTER POINT BLVD. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.
MarketBeat Community Rating for Denali Therapeutics (DNLI)
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Denali Therapeutics (NASDAQ:DNLI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Denali Therapeutics in the last 12 months. Their average twelve-month price target is $24.00, suggesting that the stock has a possible upside of 30.72%. The high price target for DNLI is $25.00 and the low price target for DNLI is $23.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $24.00 | $24.00 | $24.00 | N/A |
| Price Target Upside: | 30.72% upside | 53.45% upside | 53.45% upside | N/A |
Denali Therapeutics (NASDAQ:DNLI) Consensus Price Target History
Denali Therapeutics (NASDAQ:DNLI) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Denali Therapeutics (NASDAQ:DNLI) Earnings History and Estimates Chart
Denali Therapeutics (NASDAQ:DNLI) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.56 EPS
Next Year EPS Consensus Estimate: $-1.46 EPS
Denali Therapeutics (NASDAQ DNLI) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 6/18/2018 | | | | | | | | |
| 3/19/2018 | Q4 2017 | ($0.2720) | ($0.74) | | | View | N/A |  |
(Earnings results data provided by Zacks Investment Research)
Denali Therapeutics (NASDAQ:DNLI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Denali Therapeutics (NASDAQ DNLI) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 60.98%
Denali Therapeutics (NASDAQ DNLI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/12/2017 | Douglas K Bratton | Major Shareholder | Buy | 275,000 | $18.00 | $4,950,000.00 | | |
(Data available from 1/1/2013 forward)
Denali Therapeutics (NASDAQ DNLI) News Headlines
| Source: |
|
Denali Therapeutics (NASDAQ:DNLI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Denali Therapeutics (NASDAQ DNLI) Stock Chart for Thursday, April, 26, 2018
Loading chart…
